SRD5A1: A Potential Drug Target and Biomarker for Androgen-Driven Conditions

Target Name: SRD5A1

NCBI ID: G6715

SRD5A1

SRD5A1: A Potential Drug Target and Biomarker for Androgen-Driven Conditions

SRD5A1, also known as 3-oxo-5-alpha-steroid 4-dehydrogenase 1 (ISOform 1), is a gene that encodes a protein in the steroid biosynthesis pathway. The protein produced by this gene is involved in the conversion of inactive 3-oxo-5-alpha-steroids to biologically active 5-alpha-steroids. This enzyme is a key player in the biosynthesis of androsteroids, which are important hormones that play a crucial role in various physiological processes in the body.

SRD5A1 has been identified as a potential drug target for the treatment of androgen-dependent conditions, such as androgen-induced infertility, prostate cancer, and hirsutism. The overproduction of androgens, such as testosterone, can lead to the development of these conditions, andSRD5A1 may be a useful target for treating these diseases.

In addition to its potential as a drug target, SRD5A1 has also been shown to be a potential biomarker for androgen-dependent conditions. The levels of this enzyme have been found to be elevated in individuals with androgen-dependent conditions, such as prostate cancer and hirsutism. This may suggest that SRD5A1 could be used as a diagnostic marker for these conditions.

SRD5A1 is also involved in the production of androsteroids from the W10A stage of androgen biosynthesis. During this stage, the androsteroid receptor (AR) is activated, leading to the production of androsteroids from the W10A stage. The expression of SRD5A1 has been shown to be increased in individuals with androgen-dependent conditions, which may indicate that this enzyme plays a role in the production of androsteroids in response to androgens.

Furthermore, SRD5A1 is also involved in the detoxification of androsteroids. Androsteroids, like many other drugs, can be metabolized and excreted by the liver. The metabolism of androsteroids by SRD5A1 is critical for their excretion from the body. Studies have shown that individuals with androgen-dependent conditions have lower levels of SRD5A1 than those without these conditions. This may suggest that SRD5A1 could be used as a potential biomarker for androgen-dependent conditions.

In conclusion, SRD5A1 is a gene that encodes a protein involved in the biosynthesis of androsteroids. The protein produced by this gene has been shown to be involved in the conversion of inactive 3-oxo-5-alpha-steroids to biologically active 5-alpha-steroids. In addition to its potential as a drug target, SRD5A1 has also been shown to be a potential biomarker for androgen-dependent conditions. Further research is needed to fully understand the role of SRD5A1 in androgen biosynthesis and its potential as a drug and biomarker.

Protein Name: Steroid 5 Alpha-reductase 1

Functions: Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology

The "SRD5A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRD5A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets